Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.46 |
| ▸ | CACNG8 | Q8WXS5 | 4/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.46 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | FASN | P49327 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | BCL6 | P41182 | 1/20 | 0.40 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30905530 | 0.88 | NOS3 (0.53) | NOS3NOS1NOS2GRIA1IMPDH2 | |
| SCHEMBL118018 | 0.88 | NOS3 (0.53) | NOS3NOS1NOS2GRIA1IMPDH2 | |
| SCHEMBL12246587 | 0.81 | FASN (0.51) | NOS3NOS1NOS2L3MBTL1FASN | |
| SCHEMBL31441268 | 0.81 | KDM4E (0.48) | NOS3NOS1NOS2PIN1FASN | |
| SCHEMBL17133601 | 0.81 | KDM4E (0.48) | NOS3NOS1NOS2PIN1FASN | |
| SCHEMBL17060522 | 0.81 | GAA (0.46) | GRIA1CACNG8GAAPKMPDE3B | |
| SCHEMBL18190759 | 0.79 | GRIA1 (0.50) | NOS3NOS1NOS2GRIA1CACNG8 | |
| SCHEMBL18190551 | 0.79 | GRIA1 (0.54) | GRIA1CACNG8PDE3BPDE3ADYRK1A | |
| SCHEMBL16208353 | 0.79 | HPGD (0.50) | NOS3NOS1NOS2IMPDH2IMPDH1 | |
| SCHEMBL22424875 | 0.78 | MAPT (0.53) | GAAPKML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365205-B2 | Imidazolidin-2-one compounds as PRMT5 modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-06-21 | — | — | US | claimed |
| US-20210002299-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-01-07 | — | — | US | claimed |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| EP-3697410-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TEIJIN PHARMA LTD (JP) | 2024-12-18 | — | — | EP | disclosed |
| CN-117777121-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| CN-111417394-B | Benzimidazole derivatives and uses thereof | 帝人制药株式会社 | 2023-11-07 | — | — | CN | disclosed |
| CN-110099898-B | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC | 2023-06-08 | — | — | US | disclosed |
| EP-3397629-B1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2023-04-19 | — | — | EP | disclosed |
| US-20050004133-A1 | Modulators of VR1 receptor | VERTEX PHARMACEUTICALS INCORPORATED | 2005-01-06 | — | — | US | disclosed |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-05 | — | — | US | disclosed |
| EP-1015429-B1 | BENZIMIDAZOLINONES, BENZOXAZOLINONES, BENZOPIPERAZINONES, INDANONES, AND DERIVATIVES THEREOF AS INHIBITORS OF FACTOR XA | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-12 | — | — | EP | disclosed |
| WO-2004035549-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| US-6552042-B2 | Anticoagulants | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-22 | — | — | US | disclosed |
| US-20010021775-A1 | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa | HAN QI (US) | 2001-09-13 | — | — | US | disclosed |
| US-6207697-B1 | AMIDINYL-SUBSTITUTED RINGS; ANTICOAGULANTS; THROMBOEMBOLIC DISORDERS; ANTIISCHEMIC AND ANTIINFLAMMATORY AGENTS; STROKES; SERINE PROTEASE INHIBITORS | DUPONT PHARMACEUTICALS COMPANY | 2001-03-27 | — | — | US | disclosed |
| EP-1015429-A1 | BENZIMIDAZOLINONES, BENZOXAZOLINONES, BENZOPIPERAZINONES, INDANONES, AND DERIVATIVES THEREOF AS INHIBITORS OF FACTOR XA | Du Pont Pharmaceuticals Company (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999012903-A1 | BENZIMIDAZOLINONES, BENZOXAZOLINONES, BENZOPIPERAZINONES, INDANONES, AND DERIVATIVES THEREOF AS INHIBITORS OF FACTOR XA | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365205-B2 | Imidazolidin-2-one compounds as PRMT5 modulators | PRMT5, PRMT1, PRMT7 | NOS3 327/4885NOS1 264/4885NOS2 109/4885 |
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | NOS3 4791/4885NOS1 4783/4885NOS2 4813/4885 |
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | NOS3 1175/4885NOS1 2058/4885NOS2 1427/4885 |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | NOS3 4791/4885NOS1 4783/4885NOS2 4813/4885 |
| US-20210002299-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | PRMT5, PRMT1, PRMT7 | NOS3 327/4885NOS1 264/4885NOS2 109/4885 |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | NOS3 533/4885NOS1 762/4885NOS2 603/4885 |
| US-20050004133-A1 | Modulators of VR1 receptor | TRPV1, TRPV2, TRPV3 | NOS3 4395/4885NOS1 4029/4885NOS2 4456/4885 |
| US-20010021775-A1 | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa | F12, F13B, F11 | NOS3 3811/4885NOS1 3979/4885NOS2 3995/4885 |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | NOS3 4791/4885NOS1 4783/4885NOS2 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.